At a glance
ClinicalIndex Comparison RecordN/ACompleted· 370 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Medtronic Model 4968 CapSure Epi® Steroid-Eluting Bipolar Epicardial Pacing Lead Post-approval Study
In Brief
An observational study for Arrhythmia and Heart Failure. Completed, enrolled 370 participants across 106 sites in 14 countries.
Detailed Summary
The Medtronic CapSure Epi Lead Post-approval Study will assess long-term safety of the 4968 lead. This study is part of the Medtronic System Longevity Study.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsArrhythmia, Heart Failure
CountriesAustralia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Serbia and Montenegro, Spain, Sweden, Switzerland, United States
Collaborators--
Timeline
N/ACompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 1999
First PostedFeb 2010
Primary CompletionSep 2010
TodayJul 2026
First PostedFeb 26, 2010
Enrollment StartSep 1, 1999
Primary CompletionSep 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 16.3 years ago